CENTER FOR SINGLE PHOTON-EMITTING CANCER IMAGING AGENTS

单光子发射癌症成像剂中心

• 批准号: 6782744
• 负责人: Wynn A Volkert
• 金额: $ 200万
• 依托单位: UNIVERSITY OF MISSOURI-COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-01 至 2008-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6782744
• 关键词: clinical research; neoplasm /cancer; peptides; phage display; radionuclide imaging /scanning

(Revised Abstract) DESCRIPTION (provided by applicant): The overall goal of the Center for Single Photon-Emitting Cancer Imaging Agents at the University of Missouri-Columbia (MU) is to foster interdisciplinary research to enable development of novel radiolabeled molecular imaging agents capable of selective in vivo uptake and retention in cancer cells. The Research Components and Development Projects supported by this grant are primarily focused on identification of single-photon emitting, site-directed in vivo targeting biomolecular-conjugates directed to cell surface receptors, antigens and angiogenesis markers with high specificity. Many of the bioconjugates developed in this ICMIC are designed to allow corresponding analogues labeled with particle-emitting radionuclides to be produced for potential radiotherapeutic applications. Molecular biology and biochemical techniques form the primary approach for the design and generation of new cancer targeting vectors, including in vivo phage display, combinatorial chemistry/biochemistry, and SPPS. The In vivo Cellular and Molecular Imaging Center (ICMIC) grant will provide essential support to maintain current and catalyze expansion of research teams which are composed of scientists that combine expertise in molecular biology, chemistry, radiopharmaceutical chemistry, comparative oncology, pharmacology, tumor biology and nuclear imaging. The major thrust of the research that will be conducted in the ICMIC will involve the development of 99mTc-, 111In-and 123I-labeled SPECT imaging agents. The radiolabeled bioconjugates to be designed and studied will selectively bind with high affinity to a variety of cancers, including breast, pancreatic, melanoma, lymphoma, prostate and lung cancers. Specialized Resources (Cores) supported by the ICMIC provide critical infrastructure and expertise to support cross-disciplinary research activities conducted in the Research Components and the Development Projects. The ICMIC will facilitate expansion and enhance the scope and quality of radiopharmaceutical sciences research related to development of novel, highly specific cancer targeting imaging agents. The scientific advances made in this program will foster new interdisciplinary research programs with other investigators at both this and extramural institutions, including other ICMICs and Pre-ICMICs.

（修订摘要）描述（由申请人提供）：密苏里-哥伦比亚大学（MU）单光子发射癌症成像剂中心的总体目标是促进跨学科研究，以开发能够在癌细胞中选择性体内摄取和保留的新型放射性标记分子成像剂。 该补助金支持的研究组成部分和开发项目主要集中在识别单光子发射，定点体内靶向生物分子缀合物，这些缀合物针对细胞表面受体，抗原和具有高度特异性的血管生成标记物。许多在ICMIC中开发的生物缀合物被设计成允许生产用粒子发射放射性核素标记的相应类似物用于潜在的放射性应用。分子生物学和生物化学技术形成了设计和产生新的癌症靶向载体的主要方法，包括体内噬菌体展示、组合化学/生物化学和SPPS。在体内细胞和分子成像中心（ICMIC）赠款将提供必要的支持，以保持目前和催化研究团队的扩大，由科学家组成，联合收割机结合分子生物学，化学，放射性药物化学，比较肿瘤学，药理学，肿瘤生物学和核成像的专业知识。ICMIC的主要研究方向是开发99 mTc、111 In和123 I标记的SPECT显像剂。待设计和研究的放射性标记的生物缀合物将以高亲和力选择性地结合多种癌症，包括乳腺癌、胰腺癌、黑色素瘤、淋巴瘤、前列腺癌和肺癌。 ICMIC支持的专业资源（核心）提供关键的基础设施和专业知识，以支持在研究部门和发展项目中进行的跨学科研究活动。ICMIC将促进扩大和提高放射性药物科学研究的范围和质量，这些研究与开发新型、高度特异性的癌症靶向成像剂有关。该计划取得的科学进步将促进与本机构和校外机构（包括其他ICMIC和Pre-ICMIC）的其他研究人员开展新的跨学科研究计划。